LEXICON PHARMACEUTICALS INC

LXRXNASDAQ

🏆 #2019 by market capEarnings Nov 4US Equity

$509.44▼ $6.47 (−1.27%)

Simulated price

1h—

24h▼ 1.3%

7d—

14d—

30d—

1y—

🏦Market Cap

$1.08B

Small Cap

📈Revenue Growth (YoY)

+60.2%

High Growth

📊Gross Margin

98.8%

High

💵FCF Margin

-192.2%

Thin

⚖️P/S Ratio

26.0x

Expensive

Otter Score

Weak

No chart data available for LXRX.

Trading Snapshot

Day Range: $506.00 – $512.87
52-Week Range: $1.02 – $2.68
Volume: $3.12B
Avg Volume: $2.85B
Shares Outstanding: 444.2M
Next Earnings: Aug 31, 2026

Fundamentals Snapshot

Annual Revenue: $50M
Last Q Revenue: $692,000
P/E Ratio: -16.2
P/S Ratio: 26.0x
EPS (TTM): $-0.14
Dividend Yield: 0.00%

Why Investors Own LXRX

✓High-growth profile — revenue up +51.7% YoY with expanding US Equity exposure.
✓Healthy economics — 73% gross margin and 10% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$50M▲ +55.2% YoY

Gross Margin (TTM)

73.1%▲ +1.2% YoY

Operating Income (TTM)

$4M▲ +55.2% YoY

Free Cash Flow (TTM)

$5M▲ +55.2% YoY

About LEXICON PHARMACEUTICALS INC

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.

🦦